Table 1.
Demographics and univariate analysis of LR control
| All patients |
LR recurrence |
LRC Cox univariate HR (95% CI) |
P | |||
|---|---|---|---|---|---|---|
| n | % (total) | n | % (row) | |||
| Age | ||||||
| <70 y | 28 | 72 | 6 | 21 | Reference | |
| ≥70 y | 11 | 28 | 3 | 27 | 2.16 (0.53-8.77) | NS |
| Grade | ||||||
| NA | 3 | |||||
| 1 | 4 | 11 | 1 | 25 | Reference | |
| 2 | 27 | 75 | 6 | 22 | 1.11 (0.13-9.43) | NS |
| 3 | 5 | 14 | 1 | 20 | 0.78 (0.05-13.08) | NS |
| FIGO stage | ||||||
| I | 6 | 15 | 0 | 0 | No events | |
| II | 7 | 18 | 2 | 29 | 1.30 (0.12-14.43) | NS |
| III | 19 | 49 | 6 | 32 | 1.74 (0.21-14.46) | NS |
| IV | 7 | 18 | 1 | 14 | Reference | |
| AJCC stage | ||||||
| T1-T2 N0 | 13 | 33 | 2 | 15 | Reference | |
| T3 N0 | 4 | 10 | 0 | 0 | No events | |
| T1-3 N1 | 10 | 26 | 2 | 20 | 1.22 (0.17-8.88) | NS |
| T1-3 N2 | 11 | 28 | 5 | 46 | 4.48 (0.82-24.47) | NS |
| T1-3 N3 or pelvic LN+ | 1 | 3 | 0 | 0 | No events | |
| Nodal status | ||||||
| Negative | 17 | 44 | 2 | 12 | Reference | |
| Positive | 22 | 56 | 7 | 32 | 3.20 (0.66-15.47) | NS |
| Treatment strategy | ||||||
| Definitive radiation | 13 | 33 | 5 | 39 | Reference | |
| Adjuvant radiation | 21 | 54 | 3 | 14 | 0.24 (0.06-0.99) | 0.05 |
| Neoadjuvant radiation | 5 | 13 | 1 | 20 | 0.41 (0.05-3.60) | NS |
| Surgical resection | ||||||
| No | 13 | 33 | 5 | 39 | Reference | |
| Yes | 26 | 67 | 4 | 15 | 0.27 (0.07-0.99) | 0.05 |
| Type of vulva surgery | ||||||
| Biopsy only | 13 | 33 | 5 | 39 | Reference | |
| WLE/HV/MRV | 10 | 26 | 1 | 10 | 0.19 (0.02-1.63) | NS |
| Radical vulvectomy | 16 | 41 | 3 | 19 | 0.31 (0.07-1.29) | NS |
| Radiation volume | ||||||
| Vulva only | 4 | 13 | 0 | 0 | No events | |
| Vulva, pelvis, inguinal | 35 | 87 | 9 | 26 | NS | |
| Radiation dose, Gy | ||||||
| ≤51.2 | 28 | 72 | 6 | 21 | Reference | |
| >51.2 | 11 | 28 | 3 | 27 | 1.32 (0.33-5.30) | NS |
| Brachytherapy | ||||||
| No | 31 | 80 | 7 | 23 | Reference | |
| Yes | 8 | 20 | 2 | 25 | 0.74 (0.15-3.61) | NS |
| Concurrent chemotherapy | ||||||
| No | 25 | 64 | 6 | 24 | Reference | |
| Yes | 14 | 36 | 3 | 21 | 0.96 (0.24-3.85) | NS |
| Tumor size | ||||||
| NA | 8 | |||||
| ≤3 cm | 18 | 58 | 2 | 11 | Reference | |
| >3 cm | 13 | 49 | 5 | 39 | 5.84 (1.09-31.41) | 0.04 |
| Surgical margin | ||||||
| NA | 15 | |||||
| ≥8 mm | 8 | 33 | 2 | 25 | Reference | |
| <8 mm | 10 | 42 | 1 | 10 | 0.54 (0.05-5.94) | NS |
| Positive | 6 | 25 | 1 | 17 | 0.58 (0.05-6.38) | NS |
| Depth of invasion | ||||||
| NA | 21 | |||||
| ≤9 mm | 13 | 72 | 3 | 23 | Reference | |
| >9 mm | 5 | 28 | 1 | 20 | 1.07 (0.11-10.58) | NS |
| Lymphovascular invasion | ||||||
| NA | 16 | |||||
| Negative | 12 | 52 | 3 | 25 | Reference | |
| Positive | 11 | 48 | 2 | 18 | 0.93 (0.15-5.56) | NS |
LR, locoregional; LVSI, lymphovascular space invasion; NA, unknown or not applicable; NS, not statistically significant; WLE/HV/MRV, wide local excision/hemivulvectomy/modified radical vulvectomy.
P-values in bold indicate statistically significant associations.